Numinus Wellness (CVE: NUMI) CEO Payton Nyquvest joined Steve Darling from Proactive to share news the company has formed a partnership with KGK Science to undertake a new Psilocybin extraction clinical trial.
Nyquvest telling Proactive Phase 1 of the trial will enroll 14 human volunteers and assess the safety and psychoactive properties of a Psilocybe mushroom product. That extract will be formulated at the Numinus Bioscience lab in British Columbia, Canada.
Nyquvest also saying this landmark trial would result in safety and efficacy data for a natural Psilocybin product which could subsequently be used for further research and government-approved special access or compassionate access programs.